Table 2:

Pneumonitis as a Class-Effect Toxicity of Precision Therapy for NSCLC

Note.— The table includes the incidence rates of pneumonitis for these agents used as single-agent therapy for non–small cell lung cancer (NSCLC) and not combined with other agents or radiation therapy on the basis of findings of recent meta-analyses studies (67,126,127). Data in parentheses are 95% confidence intervals. AIP = acute interstitial pneumonia, ARDS = acute respiratory distress syndrome, COP = cryptogenic organizing pneumonia, DAD = diffuse alveolar damage, EGFR = epidermal growth factor receptor, HP = hypersensitivity pneumonitis, NSIP = nonspecific interstitial pneumonia, PD-1 = programmed death-1, PD-L1 = programmed death-ligand 1.

*High-grade pneumonitis was considered to be that with a Common Terminology Criteria for Adverse Events grade of 3 or above.

^†The incidence is among patients treated with EGFR inhibitors without prior exposure to EGFR-directed therapy. The incidence was significantly higher in studies from Japan compared with studies of non-Japan origin, for all-grade (P < .001) and for high-grade (P < .001) pneumonitis.

^‡The data include patients who received osimertinib after previous treatment with conventional EGFR inhibitors. The overall incidence of pneumonitis was 4% in a recent phase III trial of first-line treatment of osimertinib for EGFR-mutant NSCLC (18).

^§The study addressed only grade 3–4 pneumonitis.